The FDA defines Real-World Evidence as the "clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of Real-world data". Although double-blind randomized trials have been the "holy grail" in clinical studies for decades, Real-World Evidence is increasingly playing an important role in health care decision. This development is partly facilitated by the use of computers, mobile devices and other digital platforms.
Given that cannabis is being used by millions of patients worldwide, without being proven as safe and effective by randomized trials, Real-World Evidence is an invaluable tool for advising clinicians and patients alike regarding safe and effective usage of medical cannabis.
In this CannX webinar, two experts of Real-World Evidence on medical cannabis will present substantial data and discuss directions for future developments.
Dr. Yuval Zolotov, Senior Research Associate, Regional Alcohol and Drug Abuse Research Center, Ben Gurion University of the Negev (Israel)
• Dr. Joshua Aviram
Postdoctoral Fellow, Prof. Meiri's Laboratory of Cancer Biology and Cannabinoid Research, Faculty of Biology, Technion –Institute of Technology (Israel)
• Mr. David Berg
President & Chief Technical Officer, Strainprint (Canada)